Cyperus Rotundus L. extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat

被引:16
|
作者
Kum, Chang-Jun [1 ]
Kim, Eun-Young [1 ]
Kim, Jae-Hyun [1 ]
Lee, Bina [1 ]
Min, Ju-Hee [1 ]
Heo, Jun [1 ]
Kim, Jong-Hyun [1 ]
Yeom, Mijung [2 ]
Sohn, Youngjoo [1 ]
Jung, Hyuk-Sang [1 ]
机构
[1] Kyung Hee Univ, Coll Korean Med, Dept Anat, Seoul 02447, South Korea
[2] Kyung Hee Univ, Coll Korean Med, Acupuncture & Meridian Sci Res Ctr, Seoul 02447, South Korea
关键词
Cyperus Rotundus L; Osteoclastogenesis; Receptor activator of the nuclear factor kappa B ligand; Nuclear factor of activated T-cells cytoplasmic 1; C-Fos; Ovariectomy; DIFFERENTIATION; MODEL; ACTIVATION; RECEPTOR;
D O I
10.1016/j.jep.2017.03.017
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Cyperus Rotundus L. (CyR) has been widely used for the treatment of gynecologic disorder. Recent studies have reported that CyR can prevent the formation of cystic follicles and ovarian malfunction. However, the effects of CyR on osteoclastogenesis and postmenopausal osteoporosis remain unknown. Aim of the study: This study was aimed to investigate the preventive effects of CyR on RANKL-induced osteoclast formation and ovariectomy (OVX)-induced bone loss. Materials and methods: In this in vitro study, we investigate the anti-osteoporotic effect of CyR on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis, the formation of tartrate resistant acid phosphatase (TRAP) multinucleated cells, pit formation, transcription factors such as NFATc1 and c-Fos, and mRNA expression of osteoclast-associated genes were investigated. Forty 12-weeks female Sprague-Dawley rats for in vivo effect of CyR were used and OVX rat model was determined. The rats were randomly assigned into sham group and four OVX groups, i.e. OVX with D.W; OVX with estradiol (E2, 100 mu g/kg/day), OVX with CyR-L (16 mg/kg/day), OVX with CyR-H (160 mg/kg/day). The treatment lasted for 8weeks. Results: CyR inhibited osteoclast differentiation and pit formation in the RANKL-induced osteoclastogenesis of RAW 264.7 cells. Reverse transcription polymerase chain reaction analysis also showed that CyR reduced the mRNA expression of osteoclast-associated genes such as carbonic anhydrase II, TRAP, RANK, cathepsin K, matrix metalloproteinase 9, nuclear factor of activated T cells cytoplasmic 1 (NFATc1), and c-Fos. In addition, CyR decreased protein levels of NFATc1 and c-Fos. CyR inhibited trabecular bone loss in the femur caused by OVX. Conclusion: The results of this study indicate that CyR inhibits the RANKL-induced osteoclast differentiation in RAW 264.7 cells and trabecular bone loss in OVX rats.
引用
收藏
页码:186 / 194
页数:9
相关论文
共 49 条
  • [41] Eudebeiolide B Inhibits Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Regulating RANKL-Induced NF-κB, c-Fos and Calcium Signaling
    Kim, Mi-Hwa
    Lim, Hyung-Jin
    Bak, Seon Gyeong
    Park, Eun-Jae
    Jang, Hyun-Jae
    Lee, Seung Woong
    Lee, Soyoung
    Lee, Kang Min
    Cheong, Sun Hee
    Lee, Seung-Jae
    Rho, Mun-Chual
    PHARMACEUTICALS, 2020, 13 (12) : 1 - 17
  • [42] Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways
    Wang, Gang
    Ma, Chao
    Chen, Kai
    Wang, Ziyi
    Qiu, Heng
    Chen, Delong
    He, Jianbo
    Zhang, Cheng
    Guo, Ding
    Lai, Boyong
    Zhang, Shuangxiao
    Huang, Linfeng
    Yang, Fan
    Yuan, Jinbo
    Chen, Leilei
    He, Wei
    Xu, Jiake
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [43] NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma
    Tingting Li
    Dongbiao Qiu
    Qingjiao Chen
    Apeng Yang
    Junmin Chen
    Zhiyong Zeng
    Clinical and Experimental Medicine, 2023, 23 : 1581 - 1596
  • [44] NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma
    Li, Tingting
    Qiu, Dongbiao
    Chen, Qingjiao
    Yang, Apeng
    Chen, Junmin
    Zeng, Zhiyong
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (05) : 1581 - 1596
  • [45] CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo
    Kim, Ju-Young
    Min, Jung-Youl
    Baek, Jong Min
    Ahn, Sung-Jun
    Jun, Hong Young
    Yoon, Kwon-Ha
    Choi, Min Kyu
    Lee, Myeung Su
    Oh, Jaemin
    BONE, 2015, 79 : 242 - 251
  • [46] MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and Ovariectomized Osteoporosis via Suppressing RANKL-Induced ROS Production and NFATc1 Activation through P38 MAPK Signaling Pathway
    Wang, Yuxin
    Li, Xiang
    Zhou, Shengji
    Li, Jiarui
    Zhu, Yi
    Wang, Quan
    Zhao, Fengchao
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [47] TACROLIMUS INHIBIT IL-1β AND ER STRESS-INDUCED, RANKL-MEDIATED OSTEOCLASTOGENESIS BY INHIBITING PERK, IRE1, GRP78, EIF2A, C-FOS AND NFATC1
    Lee, W. -S.
    Lee, E. -G.
    Sung, M. -S.
    Lee, C. -H.
    Lee, M. -S.
    Yoo, W. -H.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 838 - 838
  • [48] Pyrroloquinoline Quinine Inhibits RANKL-Mediated Expression of NFATc1 in Part via Suppression of c-Fos in Mouse Bone Marrow Cells and Inhibits Wear Particle-Induced Osteolysis in Mice
    Kong, Lingbo
    Yang, Chongfei
    Yu, Lifeng
    Smith, Wanli
    Zhu, Shu
    Zhu, Jinyu
    Zhu, Qingsheng
    PLOS ONE, 2013, 8 (04):
  • [49] Pyridone 6, A Pan-Janus-Activated Kinase Inhibitor, Suppresses Osteoclast Formation and Bone Resorption through Down-Regulation of Receptor Activator of Nuclear Factor-κB (NF-κB) Ligand (RANKL)-Induced c-Fos and Nuclear Factor of Activated T Cells (NFAT) c1 Expression
    Kwak, Han Bok
    Kim, Hun Soo
    Lee, Myeung Su
    Kim, Kwang-Jin
    Choi, Eun-Yong
    Choi, Min-Kyu
    Kim, Jeong-Joong
    Cho, Hae Joong
    Kim, Jeong Woo
    Bae, Ji-Myung
    Kim, Yun-Kyung
    Park, Byoung Hyun
    Ha, Hyunil
    Chun, Churl Hong
    Oh, Jaemin
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2009, 32 (01) : 45 - 50